

## HOW TO ORDER A TEST



Order the OncoNext™ Liquid test shipping kit from Genoma Group



Schedule a patient blood draw. Fasting is not required prior to a OncoNext Liquid test



Draw a blood sample (10 ml)



Fill in all required TFR information and enclose the informed consent signed from the patient



Prepare and ship the sample to Genoma for analysis.



Interpretive test report is provided to the physician within 10 days



**ONCO**  
**NEXT** **RISK**  
Next Generation Oncology Diagnostics

Detects germline mutations involved in genetic predisposition to cancer

**ONCO**  
**NEXT** **LIQUID**  
Next Generation Oncology Diagnostics

Analysis of circulating tumour DNA (ctDNA) for cancer detection and monitoring (liquid biopsy)

**ONCO**  
**NEXT** **TISSUE**  
Next Generation Oncology Diagnostics

Detects somatic mutations in tumor DNA (tDNA) from tissue samples (traditional biopsy)

### ONCONEXT™: ADVANCED MOLECULAR DIAGNOSTICS SOLUTIONS USING STATE-OF-THE-ART TECHNOLOGIES



**Test performed in Italy**  
(Rome or Milan)



Fast TAT: **10 days**



**20 years experience** in molecular diagnostics



Personalized **genetic counseling** with genetic counselors experts in discussing genetic test results and familial risks.



Laboratories **ISO 17025** accredited with groundbreaking technologies



Test available **worldwide**



Over **200.000** genetic tests/year



**Dedicated R&D team**  
Numerous peer-reviewed papers published in renowned international journals

Onconext Liquid T ENG rev.00



Liquid biopsy for detection of somatic mutations in circulating cell-free tumor DNA (ctDNA) from a blood sample



## PERSONALIZING CANCER CARE



MONITORING RESIDUAL DISEASE

“Liquid biopsy” is a non-invasive, highly sensitive and cost effective method of isolating and detecting cfDNA fragments, including circulating tumor DNA (ctDNA), from the plasma of patients diagnosed with cancer or from individuals who may have cancer. By analyzing cell-free DNA isolated from a patient’s blood, we can identify clinically relevant genomic alterations in ctDNA and match these alterations to targeted therapies and clinical trials.

|                                                                                                               |                                                                                                                           |
|---------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| Invasive and expensive                                                                                        | Non-invasive and less expensive                                                                                           |
| Specific to localized tumor site                                                                              | Less dependent on original tumor site since tumor from both primary and metastatic sites release DNA into the bloodstream |
| Assessment of tumor heterogeneity limited to section of biopsy analyzed                                       | Can capture tumor heterogeneity                                                                                           |
| Difficult to biopsy some organs                                                                               | Easy to collect sample from blood                                                                                         |
| Not viable if primary tumor has been resected or if the tumor cannot be easily visualized via imaging studies | Allows for serial evaluation in absence of detectable primary tumor or metastases                                         |
| A limited amount of tissue may be obtained for immunohistochemical and genomic analysis                       | A few copies of mutant ctDNA are sufficient for analysis                                                                  |
| Serial biopsies are difficult to tolerate                                                                     | Patient can tolerate serial blood draws for evaluation; may lead to greater compliance                                    |
|                                                                                                               | New tool that can be applied for evaluation of response to therapy and for detection of residual disease                  |
|                                                                                                               | May allow for evaluation of development of resistance                                                                     |
|                                                                                                               | May aid in early detection of cancer                                                                                      |

ONCONEXT LIQUID offers a potential alternative to surgical tumor biopsy and histological assessment, eliminating many of the difficulties and concerns associated with traditional tests, as well as a means of augmenting imaging studies and other diagnostic methods

MONITORING RECURRENCE




MONITOR

Detection of somatic mutations on circulating tumour DNA (ctDNA) for cancer monitoring

OncoNext Liquid™ Monitor test is meant for patients who have been diagnosed with cancer

Benefits provided by ONCONEXT LIQUID Monitor



OncoNext™ Liquid Monitor provides physicians actionable biomarker information to help guide treatment and find ongoing clinical trials for aggressive, metastatic, and refractory cancer patients

ONCONEXT LIQUID test looks at a panel of genes known to be somatically altered in cancer, to identify genetic alterations that may be treated with targeted therapies.

Breast

The test looks at a panel of 10 genes known to be somatically altered in breast cancer

Colon

The test looks at a panel of 14 genes known to be somatically altered in colorectal cancer

Lung

The test looks at a panel of 11 genes known to be somatically altered in lung cancer

ONCONEXT LIQUID

Monitor 15 genes

ONCONEXT LIQUID

Monitor 23 genes

ONCONEXT LIQUID

Monitor 50 genes

Genoma Group also offers oncogene panels tailored for specific indications. Contact Genoma to learn more.

A broad base of high-priority target genes are used in all OncoNext™ Liquid Monitor tests, regardless of which mutations were originally detected in the patient’s tumor. This allows detection of arising clones that may create resistance to current therapies or reveal options for additional targeted therapies,

EARLY DETECTION OF CANCER




SCAN

Detection of somatic mutations on circulating tumour DNA (ctDNA) for early detection of cancer

OncoNext Liquid™ Scan is meant for preventive surveillance of high-risk populations

Benefits provided by ONCONEXT LIQUID Scan



EXAMPLES OF HIGH RISK POPULATIONS INCLUDE, BUT ARE NOT LIMITED TO:

- Known genetic predisposition to a specific cancer (e.g. the individual carries a BRCA1 mutation);
  - Significant family history of cancer;
  - Personal history of smoking;
  - Exposure to known carcinogens (e.g. radon);
  - Prolonged radiation or UV light exposure;
  - History of hormone use (fertility drugs, progestogen-containing hormone replacement therapy)
- 

ONCONEXT LIQUID Scan test is designed to screen a set of cancer driver genes for somatic mutations that could indicate early disease:

ONCONEXT LIQUID

Scan 15 genes

ONCONEXT LIQUID

Scan 23 genes

ONCONEXT LIQUID

Scan 50 genes

MONITORING DRUG RESISTANCE

MONITORING TREATMENT EFFECTIVENESS

DEVELOPMENT OF A PERSONALIZED TREATMENT PLAN